GLMD - Galmed Pharmaceuticals Ltd. Operating income before deduction of amortization

The absence of approved analogs for the treatment of NASH creates risks of high volatility, however, the EBITDA of Galmed Pharmaceuticals (GLMD) serves as an indicator of stability, where the value 0.00 shows the current magnitude. Patents for Aramchol and lobbying efforts in the US mitigate pressure, while FDA rights protection and the high cost of clinical trials limit the entry of new players into the niche.

This indicator captures the actual cash flow from operating activities before deducting depreciation and debt service costs, allowing the investor to assess the real efficiency of the business without accounting adjustments. By analyzing the operating profit of Galmed Pharmaceuticals (GLMD), one can judge the financial stability of Galmed Pharmaceuticals during the implementation of robotic molecule screening systems and the automation of clinical trial data processing.